Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens

Molecular Carcinogenesis

Volumn 29, Issue 3, 2000, Pages 143-150

  Liu, Juehui ^a   Babaian, David C ^a   Liebert, Monica ^b   Steck, Peter A ^b   Kagan, Jacob ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Bladder cancer; Chromosome 10; Tumor suppressor gene

Indexed keywords

GENE PRODUCT;

ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CHROMOSOME 10; CONTROLLED STUDY; DELETION MUTANT; GENE INACTIVATION; GENE LOCUS; HUMAN; HUMAN TISSUE; METABOLIC INHIBITION; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, TRANSITIONAL CELL; DNA MUTATIONAL ANALYSIS; EXONS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; GENE SILENCING; HUMANS; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 0033653239     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2744(200011)29:3<143::AID-MC3>3.0.CO;2-A     Document Type: Article

References (43)

1. Cancer statistics, 2000
2. Genetic alterations in bladder cancer
3. Allelotype of human bladder cancer
4. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization
5. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer
6. Nonrandom chromosomal changes in transitional cell carcinoma of the bladder
7. Chromosomes in kidney, ureter, and bladder cancer
8. Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology
9. Chromosomal analysis of bladder cancer. III. Nonrandom alterations
10. Cytogenetic investigation on 30 bladder carcinomas
11. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
12. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
13. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta
14. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase
15. 1002 protein phosphatases?
16. Crystal structure of human protein tyrosine phosphatase 1B
17. Development of 'substrate-trapping' mutants to identify physiological substrates of protein tyrosine phosphatases
18. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer
19. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors
20. Disruption of the MMAC1 gene by deletion or mutation is a frequent event in malignant melanoma
21. PTEN1 is frequently mutated in primary endometrial carcinomas
22. PTEN/MMAC1 mutations in endometrial cancers
23. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas
24. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues
25. MMAC1 mutations in primary tumor specimens and tumor cell lines
26. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers
27. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
28. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease
29. Germline mutations in PTEN are present in Bannayan-Zonana syndrome
30. PTEN germ-line mutations in juvenile polyposis coli
31. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes
32. Design and testing of beta-actin primers for RT-PCR that do not co-amplify processed pseudogenes
33. A method to distinguish between the MMAC1 gene and its pseudogene in RT-PCR analysis of point mutations
34. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms
35. Bladder cancer: Natural history, tumor markers, and early detection strategies
36. Two molecular pathways to transitional cell carcinoma of the bladder
37. Recognition and specificity in protein tyrosine kinase mediated signalling
38. PDZ domains and the formation of protein networks at the plasma membrane
39. PDZ domains bind carboxy-terminal sequences of target proteins
40. Tissue culture model of transitional cell carcinoma: Characterization of twenty-two human urothelial cell lines
41. Identification by monoclonal antibodies of an antigen shed by human bladder cancer cells